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Abstract
Background: Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only
10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status,
the tumor staging and grading (Ki67 > 2%), and the age of onset (> 50 years) can be considered elements of suspect.
Case presentation: We describe the case of a 68-year-old man presenting symptoms compatible with hypoglycemia.
The symptoms regressed with food intake. These episodes initially occurred during physical activity, later also during
fasting. The fasting test was performed and the laboratory results showed endogenous hyperinsulinemia compatible
with insulinoma. The patient appeared responsive to somatostatin analogs and so he was treated with short acting
octreotide, obtaining a good control of glycemia. Imaging investigations showed the presence of a lesion of the
uncinate pancreatic process of about 4 cm with a high sst2 receptor density. The patient underwent exploratory
laparotomy and duodenocephalopancreasectomy after one month.
The definitive histological examination revealed an insulinoma (T3N1MO, AGCC VII G1) with a low replicative
index (Ki67: 2%).
Conclusions: This report describes a case of malignant insulinoma responsive to octreotide analogs administered pre-
operatively in order to try to prevent hypoglycemia. The response to octreotide analogs is not predictable and should
be initially assessed under strict clinical surveillance.
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Background
Insulinoma is a rare tumour representing 1–2% of all
pancreatic neoplasms [1]. It is malignant in only 10% of
cases [2]. The malignancy can be stated only in the pres-
ence of locoregional invasion into the surrounding soft
tissue, lymph node or liver metastases [3]. The dimen-
sion > 2 cm, CK19 status, the tumor staging and grading
(Ki67 > 2%), and the age of onset > 50 years can be con-
sidered indicators of malignancy [4–6]. However, in lit-
erature, there are some reports where about 40–50% of
malignant insulinomas are < 2 cm [7]. Most of malignant
insulinomas are sporadic (about 97%), even if a few cases
of association with MEN1 and 1 case of association with
type-1 neurofibromatosis have been described [8].
In affected patients, the control of glycemia before sur-
gical excision, or for a prolonged time if surgery is not
feasible, may be very problematic. Admittedly, the descrip-
tion of new cases may be of help for clinicians, who have
to deal with similar situations. We report a case of malig-
nant insulinoma associated with local infiltration, neoplas-
tic thrombosis and lymph node metastasis, in which
medical treatment with octreotide effectively counteracted
hypoglycemia before surgery. One peculiarity of this case
is represented by the fact that short acting octreotide was
used, in agreement with the surgeon, in order to avoid any
possible pharmacological interference caused by long act-
ing formulations at the time of surgery, which was per-
formed shortly after the diagnosis.
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Case presentation
A 68-year-old man presented a weight increase of 7 kg
during the last year and symptoms compatible with
hypoglycemia (objective vertigo, feeling of an empty head,
sweating, palpitations). During some of these episodes low
blood glucose levels (< 40mg/dl) were documented by
glucometer measurement. The symptoms regressed with
food intake. These episodes initially occurred during phys-
ical activity and later also during fasting.
He had no family history of endocrine disease.
At admission, his body mass index was 28 kg/m2. The
rest of the physical examination was unremarkable. Bio-
chemical assessment did not show any abnormality, and
glucose level was 70mg/dl (n.v. 65–110). Plasma cortisol
at 8 a.m. was in the normal range (394.8 nmol/l, n.v.
138–685 nmol/l), anti-insulin antibodies were negative,
chromogranin A was 69 ng/ml (n.v. 10–185), prolactin
was 247mU/l (n.v. 53–369), gastrin was 12.7 pg/ml (n.v.
< 180), PTH was 6.4 pmol/l (n.v. 1–6.8) and serum cal-
cium level was 8.8 mg/dl (n.v. 8.6–10.4).
The fasting test was performed, which was interrupted
after 12 h due to the onset of symptomatic hypoglycemia
(44 mg/dl, glucometer measurement). Plasma glucose
level was 41mg/dl, insulin level 16.3 U/L and C-peptide
1.27 nmol/l (Table 1). Per protocol, 1 mg of glucagon
was injected intravenously after interruption of the fast-
ing test and plasma glucose was measured (time 0′, 41
mg/dl; after 10 min 75mg/dl, after 20 min 94mg/dl and
after 30 min 93 mg/dl). The patient’s laboratory results
showed endogenous hyperinsulinemia, according to pub-
lished guidelines (fasting test: plasma glucose < 55 mg/dl,
with insulin and C-peptide levels > 3 U/L and > 0.2
nmol/L, respectively; glucagone test: > 25 mg/dL in-
crease of glucose levels after fasting) [9]. The short
octreotide test (subcutaneous infusion of 100 mg of
short-term octreotide at 7.00 a.m. after an overnight fast,
and blood glucose, insulin and C-peptide hourly sam-
pling for six hours) was performed to evaluate the effi-
cacy of a possible treatment with somatostatin analogs,
in order to counteract hypoglycemia [10]. No food was
allowed during the test. The test showed an increase in
plasma glucose above 100 mg/dl (Table 2), and the pa-
tient was considered to be responsive to somatostatin
analogs [10].
Additional procedures included:
– MRI, which revealed a lesion of the uncinate
pancreatic process of about 4 cm, which presented a
brief contact with the upper mesenteric artery and
a > 180° contact with the superior mesenteric vein
with suspected infiltration (Fig. 1).
– Octreoscan, which showed a lesion located in the
pancreatic site, with a high somatostatin receptor
(sstR) density (Fig. 2).
– Abdominal CT scan with contrast, which revealed a
polylobed lesion with sharp margins at the level of
the uncinate pancreas process, in contact with the
superior mesenteric vein and reaching the margins
of the superior mesenteric artery. No signs of vessels
infiltration were observed.
All these imaging procedures were indicative of the
presence of an insulinoma as the cause of endogenous
hyperinsulinemia.
Surgical treatment was scheduled. Before surgery, con-
sidering the response to the short octreotide test, the pa-
tient was treated with short acting octreotide (0.1 mcg
twice a day), obtaining a good control of glycemia by gluc-
ometer measurement, disappearance of hypoglycemic
symptoms and no recurrence of hypoglycemic episodes.
The patient underwent exploratory laparotomy and
duodenocephalopancreasectomy after one month.
The postoperative course was complicated by the ap-
pearance of a pancreatic (grade B) [11] and a biliary fis-
tula, whereby the patient was conservatively treated with
fasting and parenteral nutritional intake and subse-
quenty via a naso-enteral tube. The control CT scan,
Table 1 Fasting test results. The test has been performed according to the Endocrine Society Clinical Pratice Guidelines on adult
hypoglycemic disorders (ref [9])
12 a.m. 2 a.m. 4 a.m. 8 a.m. 10 a.m. 12 p.m.
Glucometer measurement mg/dL 111 68 67 66 62 45
Glycemia (basal 65–110mg/dL) 70 58 41
Insulin level (basal 3–17 U/L) 8.7 13.3 16.3
C-peptide (basal 0.37–1.47 nmol/L) 1.11 1.03 1.27
Table 2 Short term octreotide test. The test was performed
according to ref. [2]
0’ 1 h 2 h 3 h 4 h 5 h 6 h
Glycemia
(basal 65–110mg/dL)
54 61 116 134 133 130 122
Insulin level
(basal 3–17 U/L)
16.8 2.5 3.1 4.3 4.5 5.2 6
C-peptide
(basal 0.37–1.47 nmol/L)
1.39 0.56 0.49 0.51 0.54 0.56 0.59
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performed a month later, did not reveal intra-abdominal
spill and drainages were removed. Oral feeding was re-
sumed one month after the operation.
The definitive histological examination revealed a neuro-
endocrine tumor with insulin receptors (insulinoma) of 3.5
cm infiltrating the duodenum, retroperitoneal adipose tis-
sue, with widespread neoplastic thrombosis, and with me-
tastasis in 3 pancreatic-duodenal lymph nodes among the
48 that had been surgically removed (T3N1MO, AjCC VIII
edition G1), with a low replicative index (Ki67: 2%); radical
resection (R0). Vascular and adipose tissue infiltration by
the tumor, which are indicative of malignancy, were ob-
served. Immunohistochemical staining was positive for in-
sulin and synaptophysin (Fig. 3).
The most recent abdominal MRI, performed 6months
after surgery, did not reveal any recurrence of disease
and currently the patient is in good conditions and with
normal glycemic levels.
Fig. 1 Abdominal MRI showing a solid tumor with definite margins of the uncinate pancreatic process of 4x3x3.5 cm
Fig. 2 Octreoscan showing a lesion localized in the pancreatic site, with high sstR density
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Discussion and conclusions
Clinical hypoglycemia occurs when plasma glucose con-
centration is low enough to cause symptoms and/or
signs, which include neurological alterations. The clin-
ical feautures of hypoglycemia are non specific and it is
not possible to establish a single plasma glucose concen-
tration that definitively confirms clinical hypoglycemia.
Therefore, hypoglycemia is confirmed by the documenta-
tion of the Whipple’s triad [12], e.g. symptoms and/or
signs consistent with hypoglycemia, a low plasma glucose
concentration, and resolution of clinical alterations after
the plasma glucose concentration is increased [12, 13].
The most common cause of hypoglycemia is repre-
sented by insulin, insulin secretagogues, alcohol abuse
and drugs of different classes [14]. Hypoglycemia may
occur during sepsis and other critical illnesses, which in-
clude renal or hepatic failure. Hypoglycemia can be also
secondary to cortisol deficiency [15]. It is therefore rea-
sonable to assess plasma cortisol in the presence of
hypoglycemia, although adrenocortical failure is not a
common cause of hypoglycemia in adults in the absence
of other clinical evidence. A low plasma cortisol concen-
tration found in the presence of hypoglycemia is not per
se indicative of adrenocortical insufficiency. In fact, re-
current hypoglycemia shifts glycemic thresholds for cor-
tisol secretion [16].
Hypoglycemia may be caused by hyperinsulinism in the
absence of prior gastric surgery or after Roux-en-Y gastric
bypass for obesity [15]. It can also be associated to the
presence of anti-insulin antibodies, such as in Hirata syn-
drome [17]. Finally, hyperinsulinemic hypoglycemia may
be due to uncontrolled insulin release either from tumoral
pancreatic beta-cells or from functionally defective
beta-cells, as observed in nesidioblastosis, which is usually
seen in newborns [18].
Although rare, insulinoma is the most common neuro-
endocrine tumor of the pancreas with an annual inci-
dence of four in every 1 million persons. Malignancy is
observed in only 10% of cases [2]. The clinical manifest-
ation of insulinoma are variable and nonspecific and are
related to the presence of hypoglycemia. The symptoms,
which are often precipitated during physical exercise, be-
come typically evident after fasting. The 72-h fasting test
remains the gold standard for the diagnosis of insuli-
noma and includes the measurement of plasma glucose,
insulin, C-peptide, at the time hypoglycemic symptoms
appear [19]. We used this test for the diagnosis of pri-
mary hyperinsulinism in our case and the severe
hypoglycemia with measurable insulin levels occurred
after only 12 h unequivocally confirmed the hypothesis.
Non-invasive imaging procedures, such as CT and MRI,
are used when a the biochemical diagnosis of primary hy-
perinsulinism has been made. Invasive modalities, such as
endoscopic ultrasonography and arterial stimulation ven-
ous sampling, have frequently been shown to be superior
to non-invasive localization techniques to preoperatively
localize insulinomas [19]. Numerous studies have shown
that the cell surface in neuroendocrine tumors (NETs) ex-
press sstR and have led to the development of new
localization techniques. 11In-[DTPA-D-Phe1] octreotide
scintigraphy (Octreoscan) can be used for the localization
A
B
C
Fig. 3 a Macrosection of the neoplasia showing vascular (thin arrow) and
adipose tissue (thick arrows) infiltration by the tumor. b-c
Immunohistochemical staining for insulin and synaptophysin, respectively
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of primary tumours and their metastases in patients pre-
senting with the clinical and biochemical features of NETs
[20]. However only 20–50% of insulinoma can be dec-
tected by octreoscan with planar imaging [10, 21, 22], al-
though it has been described that the use of SPECT
improves the detection of insulinomas by octreoscan scin-
tigraphy [23]. GLP-1R imaging by 111In-DOTA-exendin-4
administration is another non-invasive diagnostic ap-
proach that may succesfully localize small insulinomas
pre- and intraoperatively [24]. Very recently, the ENETS
guidelines recommend 68Ga-DOTA-somatostatin analog
PET/CT, because it is largely superior to somatostatin re-
ceptor scintigraphy, and facilitates the diagnosis of most
types of NET lesions [25]. In our patient MRI showed the
presence of a lesion of the uncinate pancreatic process of
about 4 cm. Subsequent octreoscan revealed that the le-
sion expressed high levels of sstR.
Surgery is the first choice therapy for resectable insuli-
nomas. A pharmacological approach can be useful both
during the preoperative period, and for preventing
hypoglycaemia in insulinomas with unknown localization.
Diazoxide can prevent hypoglycemia by suppressing the
release of insulin from insulinoma cells via opening
ATP-sensitive potassium channels [26]. The use of this
drug may be limited by side effects, such as hypotension,
water retention with declining edema, hyperuricaemia,
hypertriglyceridaemia, thrombocytopenia and neutro-
penia. Somatostatin analogs represent another possible
medical strategy to suppress uncontrolled insulin secre-
tion and control the symptoms of hypoglycemia in pa-
tients with insulinoma [27]. They can be used for instance
in patients who are not eligible for surgery and when diaz-
oxide is not applicable due to its inefficiency or adverse ef-
fects. In malignant insulinomas the use of somatostatin
analogs may have an additional indication, due to the anti-
proliferative and moderate antineoplastic activity of these
molecules [28–31].
It has to be said that the response to somatostatin ana-
logs may differ according to the presence of various sub-
types of sstR on insulinoma cells. Octreotide binds
predominantly to sstR subtype 2. The absence of these re-
ceptors on insulinoma cells may aggravate hypoglycemia
when a patient is treated with octreotide. This effect may
be due to the inhibition of contra-insular hormones such
as growth hormone and glucagon by somatostatin [32, 33].
The glycemic response to somatostatin analogs in any sin-
gle patient is unpredictable and for this reason testing the
drug while the patient is hospitalized is mandatory. In the
case we described, a very good response was obtained with
octreotide administration and the patient did not experi-
ence any new hypoglycemic episode before surgery.
In summary, we have described a rare case of malignant
insulinoma in a patient with recurrent hypoglycemic epi-
sodes. The patient was successfully treated with short
acting octreotide analogs before surgery, after testing its
efficacy on glycemic control. No disease recurrence was
observed at 6 month after surgery and the condition of
the patient is currently very satisfactorily.
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